J

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

Portfolio Key Account Partner

Full-Time
No salary listed
Mid
Bachelor's
Remote in Australia
RemoteThe incumbent must reside within the territory of their responsibility.
Sales & Account ManagementAccount Management

About the job

Requirements
  • Strong ability to understand, interpret, and credibly communicate complex scientific and clinical concepts across multiple therapeutic areas in discussions with healthcare professionals, key opinion leaders, and scientific experts.
  • Deep understanding of healthcare systems, market dynamics, pricing and access strategies, payer environments, Integrated Care Systems, and stakeholder interdependencies across the care pathway.
  • Proven ability to uncover customer, system, and ecosystem insights and use them to design, execute, and adapt account and territory plans aligned to portfolio and brand strategy, customer needs, and business objectives.
  • Strong commercial acumen and ability to drive portfolio performance and achieve sales and performance targets through territory ownership, key account management, and execution.
  • Demonstrated ability to build clinical advocacy by engaging healthcare professionals, identifying and developing advocates, and using compliant multichannel engagement approaches.
  • Ability to collaborate and orchestrate cross-functional work with Medical, Medical Science Liaison, Market Access, Marketing, PRM, and headquarters teams.
  • Effective communication, influence, negotiation, and interpersonal skills to build trust, align diverse stakeholders, and engage credibly with senior clinical and non-clinical decision makers.
  • Ability to manage complex accounts and healthcare ecosystems with multiple stakeholders, touchpoints, and priorities while maintaining strategic focus.
  • Digital and data literacy, including use of CRM systems, analytics, key performance indicators, and performance data to inform decisions, monitor impact, personalise engagement, and adapt plans.
  • Understanding of omnichannel and hybrid engagement strategies, and interest in learning and applying digital tools and insights to improve customer experience and portfolio impact.
  • Strategic, agile, and entrepreneurial mindset; ability to mobilise organisational resources, adjust priorities, and focus on outcomes that create value for patients, customers, and the business.
  • Experience in the pharmaceutical or biotechnology industry, with exposure to medical and commercial functions.
  • Strong track record in account management, business development, and customer engagement.
  • Life Sciences graduate or equivalent.
  • Fully valid driving licence.
  • Ability to communicate effectively in English, verbally and in writing, to collaborate with and influence stakeholders across local, regional, and international organisations.
  • Must reside within the territory of responsibility.
  • Ability to work outside normal hours when business demands require it and manage travel to cover customers as directed.
Responsibilities
  • Act as the single point of accountability for assigned key accounts.
  • Engage key centres of excellence, thought leaders, scientific experts, and strategic stakeholders through an ecosystem-based approach to build long-term partnerships and advocacy.
  • Build clinical advocacy by engaging healthcare professionals, identifying and developing advocates, and using appropriate multichannel platforms in line with brand strategies and compliance requirements.
  • Promote the portfolio to maximise performance and sales impact through in-person, virtual, and hybrid customer engagement.
  • Achieve sales and performance targets through territory ownership, key account management, and execution of integrated account plans.
  • Create, implement, and continuously refine account plans aligned with portfolio and brand strategy, customer needs, local pathways, and access realities, with measurable outcomes.
  • Identify local and Integrated Care System-level access opportunities and work with Market Access colleagues to address prescribing and reimbursement barriers.
  • Execute brand strategies, customer initiatives, and multichannel engagement plans in collaboration with Medical and Scientific Engagement Partners.
  • Coordinate with cross-functional partners to deliver timely, compliant, value-adding engagement; share insights and align medical, commercial, and access activities.
  • Use analytics, CRM data, key performance indicators, and performance metrics to monitor progress, inform decisions, adapt account strategies, and optimise customer engagement plans.
  • Maintain accurate CRM records, including customer mapping, activity documentation, insights capture, and timely reporting in line with company standards.
  • Lead or contribute to national projects, pilots, and best-practice initiatives, and support training, capability building, and upskilling for the wider Key Account Management community.
  • Identify opportunities to enhance portfolio impact, customer value, and patient outcomes while operating in compliance with local codes, regulations, and internal policies and maintaining separation between promotional and non-promotional interactions.
Desired Qualifications
  • Experience in rare diseases or specialist models.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $1.21 billion; Jazz raised full-year guidance to $4.68 billion.
  • Actio's ABS-1230 adds first-in-class KCNT1 epilepsy upside after the September 15, 2026 close.
  • Oncology revenue exceeded $1 billion in 2025, driven by Zepzelca and Ziihera.

What critics are saying

  • Xywav faces Lupin, Teva, and Tris patent fights; generic entry threatens 2027 cash flow.
  • Xywav and EPIDIOLEX still dominate value; one patent loss or safety issue would crush earnings.
  • Jazz paid $820 million for Actio before registrational proof; ABS-1230 can still fail.

What makes Jazz Pharmaceuticals unique

  • Ziihera launched August 2026, targeting $3B-$5B across HER2-positive tumors.
  • EPIDIOLEX holds exclusivity into the late 2030s and now funds four new trials.
  • Xywav's low-sodium oxybate formulation keeps narcolepsy patients despite generic Xyrem pressure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Paid Vacation

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Axios
Oct 30th, 2026
Setara Biosciences lands $90M to advance drug pipeline

The funding will advance two clinical programs.

Yahoo Finance
Oct 16th, 2026
Jazz wins FDA approval for Ziihera as commercial chief Pearce plans to retire; 2026 guidance $4.6B+

Jazz Pharmaceuticals has won US Food and Drug Administration (FDA) approval for its cancer drug Ziihera. The approval raised the drug's projected peak sales range. Separately, chief commercial officer Samantha Pearce plans to retire by June 30, 2027, or when a successor is appointed. Jazz has started an internal and external search. In its second-quarter 2026 update, Jazz reported revenue of $1,208.3 million and raised full-year 2026 guidance to $4.60–4.75 billion. The share price still fell 7.6% after earnings. Simply Wall St's narrative projects revenue of $5.7 billion and earnings of $1.7 billion by 2029, implying a fair value of $294.27 a share.

Yahoo Finance
Sep 20th, 2026
Jazz Pharma raises zanidatamab peak sales target to $3B-$5B as oncology revenue hits $1B

Jazz Pharmaceuticals reported its oncology revenue surpassed $1 billion in 2025, marking a 32% year-over-year increase. The growth follows three recent product launches, including zanidatamab, Modeyso and Zepzelca's FORTE regimen. The company raised zanidatamab's estimated peak-sales opportunity to $3 billion-$5 billion. Jazz aims to increase HER2-directed treatment adoption in gastroesophageal cancer, where only 60% of eligible HER2-positive patients currently receive such therapy. Jazz estimates the US incidence of HER2-positive gastroesophageal adenocarcinoma at approximately 8,000 patients, with a labelled population of 3,000 to 4,000 patients. The company is also developing zanidatamab for biliary tract cancer, colorectal cancer, non-small cell lung cancer and breast cancer. Jazz maintains commercial investment whilst preserving financial flexibility for acquisitions across oncology, epilepsy and sleep disorders.

Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.